title: [Individual dose adjustment of high-dose methotrexate in clinical practice].
abstract: Since its discovery in 1948 the clinical applications of methotrexate have widened; and in order to overcome resistances to methotrexate, the concept of high-dose methotrexate has been proposed. The use of rescue by folinic acid, as well as rapid dosage of MTX coupled with pharmacokinetic studies, have permitted us to administer an optimum dose of drug, with maximum therapeutic effects, but with reduced toxicity. Individual adaptation of posology, calculated using the test dose or according to population pharmacokinetic with a Bayesian method of parameter estimation (which allows us to adjust the dose of high-dose methotrexate during its infusion) permits control of inter and intra-individual variations of this drug. After analysis of the different methods proposed, we now present the results of 778 courses of treatment by high-dose methotrexate (while separating 238 courses for osteosarcoma as these formed a homogeneous group of patients). Theoretical maximum concentration and length of infusion were decided by physicians, followed by individual adaptation of posology by pharmacologists at the sixth hour of infusion of methotrexate. This treatment unites maximum security for the patient with no serious side effects (no grade 4 toxicity according to WHO classification), while receiving an optimum dose of methotrexate. In courses of MTX for osteosarcoma, the dose of MTX can be further intensified without risk, by administering on average 65% more than the usual dose in adults (8 g/m2) and 10% more than the usual dose in children (12 g/m2).
authors.affiliation: Service d'oncologie médicale, CHU Timone, Marseille, France.
authors.forename: D
authors.initials: D
authors.lastname: Bagarry-Liégey
authors.forename: A
authors.initials: A
authors.lastname: Nicoara
authors.forename: F
authors.initials: F
authors.lastname: Duffaud
authors.forename: P
authors.initials: P
authors.lastname: Guillet
authors.forename: T
authors.initials: T
authors.lastname: Pignon
authors.forename: J
authors.initials: J
authors.lastname: Catalin
authors.forename: A
authors.initials: A
authors.lastname: Durand
authors.forename: R
authors.initials: R
authors.lastname: Favre
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001499:Bayes Theorem; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008722:Methods; D008727:Methotrexate / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate